Advanced Pancreatic Carcinoma Clinical Trial
Official title:
Ensayo Fase II de selección Individualizada Del Tratamiento de Quimioterapia en Pacientes Con Carcinoma de páncreas Avanzado en función de la determinación de Dianas terapéuticas en el Tejido Tumoral
The purpose of this study is to determine the proportion of patients alive after 12 months of the beginning of the trial in patients with advanced pancreatic carcinoma individually selected and grouped according to the expression in tumor tissue for therapeutic targets.
Status | Completed |
Enrollment | 31 |
Est. completion date | December 2014 |
Est. primary completion date | October 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Histological or cytological diagnosis of pancreatic carcinoma. - Patients> 18 years. - Measurable or not measurable disease. - Life expectancy> 3 months at the discretion of the investigator. - Good general condition determined by the ECOG scale (score 0-1) - Candidate for first-line systemic chemotherapy according to standard practice. - Availability of tumor tissue or opportunity for tumor biopsy for the - determination of biomarkers and their correlation with treatment. - Adequate hematologic function: ANC> 1.5 x 103 / L, absolute count of platelets> 100 x 109 / L, normal values of INR and PTT. - Adequate liver function: total serum bilirubin <2 mg / dL, ALT and AST <3 times the upper limit established by the laboratory (LSR) or <5 LSR in patients with liver metastases. - Adequate renal function: serum creatinine <1.5 LSR. Exclusion Criteria: - Patients who have received prior chemotherapy for advanced pancreatic carcinoma. Will not result excluding patients who had previously received adjuvant treatment with gemcitabine or fluoropyrimidines. Also not will be excluded patients who had previously received preoperative neoadjuvant treatment for localized disease with chemotherapy and / or radiotherapy. - Patients for whom is contraindicated the administration of either drug used in first-line treatment for pancreatic cancer: Gemcitabine, 5'Fluouracilo, Leucovorin, Capecitabine, Oxaliplatin, Irinotecan, Erlotinib. - Pregnant or breastfeeding women |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Spain | Hospital Universitario de Fuenlabrada | Fuenlabrada | Madrid |
Spain | Hospital Universitario Madrid Sanchinarro | Madrid |
Lead Sponsor | Collaborator |
---|---|
Centro Nacional de Investigaciones Oncologicas CARLOS III | Apices Soluciones S.L., Grupo Hospital de Madrid, Hospital Universitario de Fuenlabrada |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall survival | The primary endpoint is survival as measured from the start of treatment the patient to the death of the patient according to the Kaplan-Meier. For each treatment arm will determine the overall survival and the survival and actuarial survival at one year | 12 months | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05304936 -
HCW9218 for Advanced Pancreatic Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05620732 -
Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T
|
N/A | |
Recruiting |
NCT05053971 -
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas
|
Phase 1/Phase 2 | |
Recruiting |
NCT05733000 -
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05143151 -
CD276-targeted Chimeric Antigen Receptor T Cells in Treatment With Advanced Pancreatic Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05238831 -
SMMART Adaptive Clinical Treatment (ACT) Trial
|
Early Phase 1 | |
Recruiting |
NCT05759923 -
First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours
|
Phase 1 | |
Recruiting |
NCT05526443 -
Austrian Registry for Evaluation of Treatment Patterns and Outcome in Patients With Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
|
||
Not yet recruiting |
NCT05257122 -
A Phase II Clinical Trial of Fruquintinib as Third Line Treatment in Advanced Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT03033225 -
Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study
|
Phase 2 | |
Recruiting |
NCT05969860 -
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
|
Phase 2 | |
Recruiting |
NCT04550494 -
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
|
Phase 2 |